What's Up, Corporate Finance?
“Will it Get Better Again? Our M&A Outlook for 2024” With Dr. Christian Zuleger
December 12, 2023
Our partner Dr. Christian Zuleger was a guest in the 100th edition of the podcast What's Up, Corporate Finance? As an authority on the M&A market, he spoke with host Bastian Frien about key learnings from 2023 and promising market trends in the small, mid and large cap segment. Topics include the changing preferences in the area of ESG funds and the increasing acceptance of buy-and-build-strategies. In addition to Mr. Zuleger, Jürgen Zapf (Alvarez & Marsal) and Dr. Sven Oleownik (EMERAM) provide interesting insights into the development of the market.
*Please note that the podcast is available in German only
Author: Bastian Frien
Quotes from Dr. Christian Zuleger
- “In the large cap segment in particular, fund managers have a smaller number of promising targets at their disposal. As a result, we see that they prefer to realize an increase in value and therefore place their targets in a continuation fund.”
- “W&I insurance is becoming increasingly relevant, especially for financial investors. This means that due diligence is becoming more complex because insurance companies are carrying out more detailed checks.”
- “We observe traditional and diversified financial investors increasingly moving into the ESG sector and favoring such assets over other segments.”
- “Transactions in the small cap market are showing an increasing degree of creativity. U.S. investors, who have already successfully implemented various buy-and-build-strategies in highly fragmented sectors in their home market, are now bringing these approaches to Europe.”
得意分野
Suggested News & Insights
Global ESG and Sustainability Update: Reporting & Due Diligence Developments and Compliance StrategiesTuesday, May 19, 2026Sidley Matter Named “Deal of the Year” at D CEO Mergers & Acquisition Awards 2026May 5, 2026Sidley Represents MSA Safety in US$555 Million Acquisition of Autronica Fire and SecurityMay 5, 2026Sidley Represents Siris Capital in Its US$4.2 Billion Sale of EquinitiMay 5, 2026Sidley Represents Archimed in US$1.1 Billion Acquisition of Esperion TherapeuticsMay 1, 2026Sidley Represents Apollo on its Strategic Investment in vVARDISApril 30, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory
